MAPK3 and breast carcinoma: GPER has been shown to modulate ERK1/2 and Akt activity, which is dependent upon trans-activation of the epidermal growth factor (EGF) receptor via release of heparin-bound EGF (HB-EGF) in breast cancer cells [25].